BioCentury on BioBusiness,
Finance
How JOBS Act rules could make it easier for small biotechs to go public
Tear down that wall
By Stacy Lawrence
Senior Writer
Published on
Monday, April 16, 2012
Lawyers and bankers are trying to sort out the new IPO process
- including the revival of sellside analyst participation - in the wake of the
Jumpstart Our Business Startups Act. But they aren't likely to make much
headway until the SEC and the Financial
Industry Regulatory Authority have completed their rulemaking
processes.
The JOBS Act marks the first
break in the wall between banking and research since Eliot Spitzer went after
the investment banking industry in the early 2000s. The changes come almost a
decade after the settlement between regulators and major Wall Street firms
effectively removed sellside analysts from the public offering process.
105
words displayed of
2288
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]